FDA approves colchicine as first anti-inflammatory drug for CV prevention

Colchicine (Lodoco) is indicated to reduce the risk of MI, stroke, coronary revascularization, and CV death in adult patients with established atherosclerotic disease or with multiple risk factors for CV disease. In the LoDoCo2 trial, 0.5 mg of colchicine once daily resulted in a 31% lower relative risk of the primary composite endpoint compared with placebo.